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Abstract
While most drugs of abuse increase dopamine neurotransmission, rapid neurochemical measurements show that different drugs
evoke distinct dopamine release patterns within the nucleus accumbens. Rapid changes in dopamine concentration following psy-
chostimulant administration have been well studied; however, such changes have never been examined following opioid delivery.
Here, we provide novel measures of rapid dopamine release following intravenous infusion of two opioids, morphine and oxyco-
done, in drug-na€ıve rats using fast-scan cyclic voltammetry and rapid (1 min) microdialysis coupled with high-performance liquid
chromatography - tandem mass spectrometry (HPLC-MS). In addition to measuring rapid dopamine transmission, microdialysis
HPLC-MS measures changes in GABA, glutamate, monoamines, monoamine metabolites and several other neurotransmitters.
Although both opioids increased dopamine release in the nucleus accumbens, their patterns of drug-evoked dopamine transmis-
sion differed dramatically. Oxycodone evoked a robust and stable increase in dopamine concentration and a robust increase in
the frequency and amplitude of phasic dopamine release events. Conversely, morphine evoked a brief (~ 1 min) increase in
dopamine that was coincident with a surge in GABA concentration and then both transmitters returned to baseline levels. Thus,
by providing rapid measures of neurotransmission, this study reveals previously unknown differences in opioid-induced neuro-
transmitter signaling. Investigating these differences may be essential for understanding how these two drugs of abuse could
differentially usurp motivational circuitry and powerfully influence behavior.
Introduction
Opioids, particularly l-opioid receptor (MOR) agonists, are com-
monly prescribed for pain management. However, opioids can cause
molecular and cellular adaptations which promote physical and
behavioral dependencies, and the development of addiction is there-
fore a major concern (Williams et al., 2001). Indeed, prescription
opioid abuse has increased dramatically over the past decade
(Compton & Volkow, 2006). More recent generations of opioids
(e.g. oxycodone, hydrocodone and fentanyl) are tremendously effec-
tive for pain management and, while it was initially suggested that
oxycodone is unlikely to be more addictive than morphine (Davis
et al., 2003), oxycodone is widely abused and is among the fastest
growing drugs of abuse (Compton & Volkow, 2006). While this is
certainly inﬂuenced by greater availability due to prescription use,
recent studies suggest that oxycodone may have a higher potential
to promote addiction-related behaviors than other opioids, such as
morphine (Stoops et al., 2010; Comer et al., 2013). However, little
is known about how oxycodone and morphine differentially inﬂu-
ence changes in brain function associated with drug abuse and
addiction.
While the mechanisms underlying drug addiction are complex
and still intensely debated, dopamine (DA) neurotransmission is
incontrovertibly involved in the development, maintenance and
compulsive intake of abused drugs (Phillips et al., 2003a; Robinson
& Berridge, 2003; Hyman et al., 2006). Despite different mecha-
nisms (L€uscher & Ungless, 2006), all abused drugs increase DA
transmission within the nucleus accumbens (NAc) (Di Chiara &
Imperato, 1988; Nestler & Malenka, 2004). Techniques that allow
for rapid measures of DA release have revealed that different drugs
elicit distinct DA signaling dynamics, and these better inform our
understanding of the neurochemical consequences of drug intake
(Cheer et al., 2007; Aragona et al., 2008; Daberkow et al., 2013).
Further, additional neurotransmitter systems, such as glutamate and
GABA, within the NAc are critical for reward and motivation (Kel-
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ley, 2004; Wydra et al., 2013; Shen et al., 2014). Given the impor-
tance of these neurotransmitter systems in the regulation of behav-
iors associated with drug abuse, and that there is currently no
information regarding rapid neurotransmission following opioid
delivery, we aimed to determine whether rapid changes in these
systems within the NAc differ following morphine or oxycodone
delivery.
Given the explosive rise in prescription opioid abuse (Compton &
Volkow, 2006), the speculation that oxycodone may more potently
promote drug addiction (Comer et al., 2008), and the important role
for increased DA transmission in behaviors associated with drug
abuse and addiction, we hypothesised that oxycodone, compared to
morphine, would more robustly enhance extracellular DA concentra-
tions ([DA]) within the NAc. Here, we employed two advanced
in vivo measurement technologies, fast-scan cyclic voltammetry
(FSCV) and rapid-sampling microdialysis with high-performance
liquid chromatography coupled with mass spectrometry (HPLC-MS)
to provide a sub-second (phasic) and minute-to-minute comparison
of morphine- and oxycodone-evoked alterations in DA release.
Additionally, microdialysis with HPLC-MS allowed the determina-
tion of whether these drugs differentially alter neurotransmission
patterns across a wide range of signaling molecules known to be
important for both modulating DA signaling and mediating reward,
motivation and drug addiction.
Materials and methods
Subjects
Thirty-seven male Sprague–Dawley rats (~ 300 g) were obtained
with indwelling jugular vein catheters (Charles River Laboratories,
Raleigh, NC, USA) and were used as subjects (FSCV morphine,
n = 8; FSCV oxycodone, n = 8; FSCV naloxone–morphine or oxy-
codone, n = 9; HPLC-MS dialysis morphine, n = 4; HPLC-MS dial-
ysis oxycodone, n = 5). Rats were maintained on 12:12-h reverse
light:dark cycle (lights off at 08.00 h). Rats were housed individu-
ally with ad libitum access to food and water. All procedures were
conducted in accordance with the National Institute of Health Guide
for the Care and Use of Laboratory Animals and were approved
by the University of Michigan Committee on the Use and Care of
Animals.
Surgery
Rats were anesthetised with intramuscular ketamine hydrochloride
(90 mg/kg) and xylazine hydrochloride (10 mg/kg). For FSCV sub-
jects, a guide cannula (Bioanalytical Systems, West Lafayette, IN,
USA) was secured dorsal to the NAc core (AP, +1.3; ML, 1.3;
DV, 2.5 mm relative to bregma) or shell (AP, +1.8; ML, 0.8;
DV, 2.5 mm) and a Ag/AgCl reference electrode was placed in
the contralateral cortex (AP, 0.8; ML, 3.0; DV, 2.5 mm rela-
tive to bregma). A bipolar stimulating electrode (Plastics One, Roa-
noke, VA, USA) was lowered into the ventral tegmental area
(VTA; AP, 5.2; ML, 0.8 mm relative to bregma) until electri-
cally-evoked DA release within the striatum was detected, as
described previously (Wightman et al., 2007). Similarly, microdial-
ysis subjects were implanted with a guide cannula (CMA, Hollis-
ton, MA, USA) positioned 1 mm above the NAc (AP, +1.7; ML,
0.9; DV, 6.0 mm). All implants were permanently secured to
the skull with stainless steel surgical screws and dental acrylic.
Following surgery, rats recovered for ~ 5 days until they reached
pre-operative weight.
Experimental procedures: FSCV
On the day of the pharmacological experiment, a recording cable
was anchored to the skull cap and connected to a rotating commuta-
tor (Crist Instruments, Hagerstown, MD, USA) suspended from the
top of the test chamber allowing rats to move freely about the Plexi-
glas recording chamber. Vehicle-loaded tubes were threaded through
the rotating commutator and along the headstage cable, and attached
to the i.v. catheter and a syringe pump outside of the test chamber.
Carbon-ﬁber microelectrodes (~ 120 lm in length) were lowered
into the NAc core or shell and secured in locations where both elec-
trically-evoked and naturally occurring phasic DA release events
were detected (Wightman et al., 2007).
Similar to our previous FSCV studies (Aragona et al., 2008;
Porter-Stransky et al., 2011), experiments began with a 15-min base-
line recording interval followed by another 15-min recording that
controlled for i.v. vehicle administration (0.2 mL of sterile saline;
5 s). Rats were then administered, at 15-min intervals, cumulative
doses of morphine sulfate (Sigma, St Louis, MO, USA) or oxycodone
hydrochloride (Sigma) dissolved in sterile saline (0.2 mL; 5 s).
Following saline injections, separate groups of animals received infu-
sions of either oxycodone or morphine according to the following
doses: low dose, 0.1 mg/kg; medium dose, 0.5 mg/kg; and high dose,
1.0 mg/kg i.v. Drug doses were chosen based on what rats self-
administer with the lowest dose under morphine self-administration
thresholds (Mierzejewski et al., 2003). The clinical morphine-to-
oxycodone potency ratio has been shown to be between 1 : 1 and
1 : 1.5, with large individual differences in bioavailability (Davis
et al., 2003). As such, oxycodone doses were kept equivalent to mor-
phine doses.
Another control, using the MOR-preferring antagonist naloxone,
was conducted to test the involvement of MORs in the opioid-
evoked increases in DA transmission identiﬁed in the present study.
A separate group of rats received baseline and saline recording peri-
ods followed by a pre-exposure of naloxone, 3.0 mg/kg, i.v. (Tocris,
Bristol, UK). Fifteen minutes after the naloxone infusion, either
morphine or oxycodone (0.5 mg/kg) was administered because this
dose consistently elicited a similarly initial increase in [DA]. For all
subjects, the ﬁnal recording session was followed by administration
of a DA autoreceptor blocker, the D2-type receptor antagonist raclo-
pride (Sigma; 1.0 mg/kg i.v.; 5 s) as a positive control. This dose
of raclopride blocks somatodendritic and terminal autoreceptors
(Andersson et al., 1995) and robustly increases DA transients and
[DA] (Aragona et al., 2008).
FSCV data acquisition
Carbon-ﬁber microelectrodes were lowered into the NAc core or
shell and a negative holding potential of 0.4 V was applied. Then,
at 10 Hz, a triangular voltage ramp was applied (Fig. 1A; oxidative
scan, 0.4 to 1.3 V; reductive scan, 1.3 to 0.4 V at a rate of
400 V/s); this results in a large and highly consistent change in cur-
rent that is recorded from the carbon surface (Robinson et al., 2003)
(Fig. 1A, insets i–iv). As the charging currents resulting from these
voltage ramps are stable (Robinson et al., 2003), they are continu-
ally background-subtracted in order to examine the changes in cur-
rent associated with changes in concentration of electroactive
species surrounding the carbon ﬁber (Fig. 1B–D) (Robinson et al.,
2003). As such, FSCV data are presented as a delta, and back-
ground-subtracted data are the norm for measuring phasic changes
in neurotransmission, including DA release (Garris & Wightman,
1994; Phillips et al., 2003b; Willuhn et al., 2012). Current changes
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are detected at the surface of the carbon-ﬁber microelectrodes, and
changes beyond those caused by the charging current are plotted in
false color against time and the applied voltage ramp (Fig. 1B)
(Michael et al., 1999). This allows convenient visualisation of neu-
rochemical changes across the entire applied voltage ramp. With this
particular optimisation, FSCV robustly detects changes in [DA] as
well as changes in local pH (Fig. 1D and E) (Venton et al., 2003;
Roitman et al., 2004; Takmakov et al., 2010; Badrinarayan et al.,
2012). Here, we show current changes measured at the carbon ﬁber
during electrical stimulation of DA neurons with and without back-
ground subtraction (Fig. 1C) and one can easily see that the DA
released by the stimulation causes a increase in current beyond that
produced by the charging voltage of the applied potential needed to
measure phasic DA with FSCV.
Speciﬁc chemical species are identiﬁed by their characteristic
change in current and this is identiﬁed by the shape of its cyclic vol-
tammogram (CV; Fig. 1D) (Robinson et al., 2003; Heien et al.,






Fig. 1. Measuring real-time neurochemical transmission dynamics with background-subtracted FSCV. (A) The carbon-ﬁber microelectrode is held at 0.4 V
for 90 ms between voltage ramps. This ‘adsorption phase’ attracts positive electroactive analytes because of the negative potential applied and causes them to
adsorb onto the carbon surface. At a rate of 10 Hz, the holding potential is rapidly ramped (400 V/s) to a positive voltage (1.3 V; ‘oxidative scan’) and then
back down to the negative holding potential (0.4 V; ‘reductive scan’). This triangular scan produces a highly robust increase in current at the carbon surface,
called the ‘charging current’ (insets i to iii in A). Each scan (which has a corresponding CV; see below) is represented along the x-axis [150 measures
(150 CVs) in 15 s]. Highlighted are several representative scans and the resulting current changes which they cause. (B) Background-subtracted changes in cur-
rent measured during the triangular ramp are plotted in false color across the change in voltage associated with the ramp (0.4 to 1.3 V, then back to 0.4 V;
plotted on a straight line along the y-axis). (C) Each voltage ramp generates a robust charging current. The charging current is extremely stable which allows
for FSCV data to be background-subtracted. This process permits acute current surges beyond that of the charging current to be detected. (D) Unique CVs from
three different ramps (from scans 16, 52 and 76) are shown (i to iii respectively). These demonstrate how small the acute changes in current caused by changes
in neurochemical concentration are relative to the magnitude of the charging current (as the inset in Fig 1C shows, the red scan is slightly larger than the back-
ground scan). CVs from the three selected ramps; the approximate difference in current is shown for each CV (16, 52 and 76). The blue scan (D i) shows a typ-
ical charging current, after background subtraction, (taken from a location in the color plot where there was not an obvious change in color). Conversely, the
red scan (D ii) shows the current at scan 52 which is 200 ms after the DA neurons in the VTA received electrical stimulation (yellow box). The CV reveals an
increase in current caused by an increase in DA concentration at the recording site. Electrical stimulation also elicited an expected delayed decrease in current
attributed to a basic shift in pH. The CV for this is shown by scan 76 in D iii. (E) Color plot resulting from a representative infusion of oxycodone (blue box).
Two reliable neurochemical events are evoked by opioid infusion, an increase in DA concentration and an acidic shift in pH. (F) [DA] trace (red), which corre-
sponds to the upper vertical dotted line in Fig 1E, and DA transients are clearly visible (triangles). Mean [DA] change (bar graph inset) can be determined by
averaging a period of time prior to the infusion (light gray bar) and a time period after the infusion (dark gray bar). The inset shows that further transient analy-
sis (amplitude and half-width) provides further resolution underpinning DA transmission. (G) Phasic changes in acidic pH following oxycodone delivery (blue
box).
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‘ﬁngerprints’ that identify each electroactive species because of their
unique oxidation and reduction reactions during the voltage ramp
(Phillips et al., 2003a). Following background subtraction, as mini-
mal changes in current occurred before the representative electrical
stimulation shown, the CV just prior to the stimulation shows very
low changes in current (Fig. 1, D-i, scan 16). However, electrical
stimulation of the VTA caused a rapid increase in current at the
peak oxidation potential for DA (Fig. 1B and D-ii, scan 52). As
reliably shown in previous studies, electrical stimulation of DA neu-
rons was also followed by a slow and long-lasting change in basic
pH (Fig. 1E and G) compared to evoked DA. To convert current to
[DA] and pH units, electrodes were calibrated in a microﬂuidic ﬂow
system (Sinkala et al., 2012) with solutions of known DA concen-
tration and differing pH values to generate calibration curves (Ba-
drinarayan et al., 2012). Recorded CVs were converted from current
into [DA] using principal component analyses using electrically-
evoked DA and pH CVs acquired before and after each experiment
as training sets for principal component analysis (Heien et al., 2005;
Keithley et al., 2009; Keithley & Wightman, 2011). This allows the
separation of DA from pH and the conversion of current changes
into nM concentations for DA and pH units (Heien et al., 2005; Ke-
ithley et al., 2009; Keithley et al., 2010). Electrical stimulations of
the VTA were used to optimally place FSCV electrodes within the
NAc, to verify electrode ﬁdelity throughout the experiment, and to
generate training sets.
FSCV analysis
As in our previous experiments (Porter-Stransky et al., 2011;
Badrinarayan et al., 2012), carbon-ﬁber electrodes were constructed
in all aspects as described previously (Robinson et al., 2003)
except that epoxy was applied to the seal where the carbon meets
the glass encasement. Waveform generation, data collection, ﬁlter-
ing and analysis were performed as previously described (Wight-
man et al., 2007). A DA transient was deﬁned as a ﬁve-fold or
greater phasic surge in [DA], relative to the root-mean-square noise,
that was ~ 1 s in duration (Fig. 1F) (Phillips et al., 2003a). Data
were collected in 30-s ﬁles and background-subtracted at approxi-
mately the lowest current value. Current was converted to [DA]
using principal component analysis (Keithley & Wightman, 2011),
and transient detection and quantiﬁcation were achieved using
MATLAB (code provided by Dr Richard Keithley) and MINIANALYSIS
(Synaptosoft, Decatur, GA, USA), respectively. As established in
previous studies (Aragona et al., 2008, 2009; Badrinarayan et al.,
2012), transients < 20 nM were not included in the analysis because
events below this magnitude are not reliably detected across
electrodes.
Microdialysis with HPLC-MS
As the FSCV studies used here are highly optimised to measure
changes in DA and pH, we employed rapid microdialysis coupled
with a novel HPLC-MS method (Song et al., 2012) to measure
1-min changes in [DA], as well as changes in 15 additional neuro-
chemical species, with high sensitivity. Dialysate samples were
collected and prepared as previously described (Song et al., 2012).
Brieﬂy, at the beginning of microdialysis experiments, a 1-mm
probe was inserted into a guide cannula to target the NAc. Micro-
dialysis probes were perfused at 2 lL/min for 1.5 h prior to sample
collection using a Fusion 400 syringe pump (Chemyx, Stafford,
TX, USA). Samples were then collected every 60 s, yielding 2-lL
samples. Immediately after dialysate collection, the following
reagents were added to each 2.0-lL dialysate fraction: 1.5 lL of
borate buffer (sodium tetraborate, 100 mM), 1.5 lL benzoyl chlo-
ride in 2% acetonitrile, 1.5 lL of stable-isotope labeled internal
standard solution, and 1.5 lL d4-acetylcholine (ACh) internal stan-
dard solution (Song et al., 2012) (Fig. 9A). Resulting fractions
were analysed using a nanoAcquity HPLC system (Waters, Mil-
ford, MA, USA) equipped with a Waters 1 9 100 mm HSS T3
reverse-phase HPLC column operated at 100 lL/min. Eluting ana-
lytes were detected using an Agilent 6410 triple quadrupole MS
(Agilent, Santa Clara, CA, USA) operating in positive mode
performing dynamic multiple-reaction monitoring. The following
compounds were monitored in dialysate by the HPLC-MS method:
DA and its metabolites 3-methoxytyramine (3-MT), homovanillic
acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC); norepi-
nephrine and its metabolite normetanephrine; serotonin and its
metabolite 5-hydroxyindole-3-acetic acid; adenosine; histamine;
aspartate; serine; taurine; glutamate; and GABA (Fig. 9A and B).
ACh, which cannot be labeled with benzoyl chloride, was detected
directly.
We collected 15 baseline samples and ﬁve samples following an
i.v. saline infusion. Next, subjects received an i.v. infusion (200 lL)
of 0.5 mg/kg of either morphine or oxycodone, and fractions were
collected for 15 min. These doses were chosen because FSCV stud-
ies revealed that these doses evoked similar magnitudes in peak
increases in [DA] evoked by drug infusion and caused similar dura-
tions in behavioral immobility (data not shown). As cocaine in the
presence of an autoreceptor blocker (the D2-type antagonist raclo-
pride) has been shown to synergistically increase [DA] (Rouge-Pont
et al., 2002; Aragona et al., 2008), co-infusions of raclopride and
cocaine were administered as a positive control in a subset of sub-
jects. Speciﬁcally, 1 mg/kg, i.v. raclopride was administered at the
end of the experiment and was followed 10 min later by 3 mg/kg,
i.v. cocaine infusion. Dialysate was collected for 10 min following
these infusions.
Statistics
To compare mean changes from pre-infusion basal levels in [DA]
measured by FSCV across all drug doses, 120-s sampling periods
were averaged into 10-s or 1-s bins and a linear mixed model
was utilised because of its ability to handle repeated-measures
data in which observations are not independent (Aragona et al.,
2008). Comparisons of transient frequency, amplitude and half-
width following drug treatment compared to mean saline values
were also determined using linear mixed-model regressions (data
binned into 1-min bins for the duration of the 15-min recording
period). Potential core–shell differences were assessed using a
liner mixed model by including the region as a ﬁxed-effect vari-
able. To compare mean changes in DA transients across entire
recording sessions, transient frequency, amplitude and half-width
per min across drug doses were compared to control infusions of
saline using one-way ANOVAs with Bonferroni post-test corrections
for multiple comparisons. For microdialysis data, neurotransmitter
concentrations were normalised and converted to percentages of
baseline. To statistically determine drug-induced changes in neuro-
transmitter and metabolite levels, a linear mixed model was uti-
lised. The linear mixed models calculated speciﬁc t- and P-values
for each time point as well as conducting an omnibus F-test. F-
values are reported to examine overall main effects and t-values
are reported to assess differences for speciﬁc time points and are
corrected for multiple comparisons. The signiﬁcance of each time
point was determined when calculated t-values crossed the thresh-
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old of the critical t-value, which corresponded to an a level of
0.05. Degrees of freedom were adjusted based on the distance
between comparisons in this model. All statistical analyses were
conducted using SPSS version 19 for Windows, and graphs were
generated in Graph Pad Prism and Adobe Illustrator. All data are
presented as mean  SEM and an a level of 0.05 was used for
determining statistical signiﬁcance (*) for all analyses. An a level
of 0.09 was used to indicate trending signiﬁcance (#).
Histology
Following experiments, carbon-ﬁber FSCV electrodes were removed
and rats were killed with ketamine (0.2 mL i.v.). In FSCV subjects,
an electrolytic lesion was made to mark the location of the recording
electrode using a tungsten electrode at the location of the recording
site through the guide cannula at the microdrive setting used during
testing (Aragona et al., 2008). Probe placement for microdialysis
studies could be determined easily with light microscopy upon
removal of the probe, using the same histological preparations.
Brains were removed and post-ﬁxed in formalin. Brains were sec-
tioned into 40- to 50-lm coronal slices on a cryostat and stained
with Cresyl violet to verify electrode placement.
Results
Dramatic differences in dopamine concentration evoked by
morphine and oxycodone
Detection of naturally-occurring transients is necessary for accurate
FSCV measurements of pharmacologically-induced changes in DA
transmission (Wightman et al., 2007); therefore, carbon-ﬁber elec-
trodes were lowered into the NAc core or shell to locations where
both electrically-stimulated DA release and naturally-occurring pha-
sic release occurs (i.e. DA transients). A representative color plot
(Fig. 2A) and corresponding traces (Fig. 2B and C) demonstrate that
i.v. infusion of morphine resulted in a rapid increase in [DA]
(Fig. 2B) and an acidic shift in pH (Fig. 2C).
To quantify these data, [DA] was binned every 10 s and drug-
evoked changes were compared to those following control infusions
of saline. The low dose (0.1 mg/kg) infusion of morphine signiﬁ-
cantly elevated [DA] only within the ﬁrst bin immediately following
drug infusion (Fig. 2D; t79.149 = 2.133, P = 0.036). Following the
medium dose (0.5 mg/kg), morphine evoked signiﬁcant increases in
[DA] for the ﬁrst (t76.088 = 2.491, P = 0.015), second
(t81.698 = 5.591, P < 0.001) and third (t83.963 = 3.229, P = 0.002)
bins following drug infusion (Fig. 2E). As with the low dose, the
high dose (1.0 mg/kg) of morphine evoked increases in [DA] only
within the second bin following drug infusion (Fig. 2F;
t69.705 = 3.587, P = 0.001).
To test whether these increases in DA release were mediated by
activation of MORs, we conducted an additional experiment in
which subjects were pretreated with the MOR antagonist naloxone





Fig. 2. Average acute changes in dopamine concentration and local pH in
the NAc evoked by i.v. morphine. (A) A representative color plot shows
increased DA transmission (top white line) and an acidic shift in local pH
(bottom white line) following i.v. administration of the high dose of mor-
phine (1.0 mg/kg). (B) Current was converted into [DA] and trace is repre-
sentative of the peak DA oxidation potential. Select DA transients were
identiﬁed and their respective amplitudes are given. (C) Similarly, current
from the representative color plot was converted into changes in pH units
and the pH trace was taken from the lower dotted white line on the color
plot. (D–I) Change in [DA] and pH units were binned every 10 s across a
120-s sampling window for statistical comparison to pre-infusion values. (D–F)
Changes in [DA] during infusions of cumulatively increasing doses of
morphine compared to control infusions of saline. (D) Following the low
morphine dose (0.1 mg/kg, i.v.), [DA] was increased in the second time bin.
(E) Following the medium morphine dose (0.5 mg/kg, i.v.) [DA] was
increased in the ﬁrst, second and third time bins. (F) As with the low dose,
following the high morphine dose (1.0 mg/kg, i.v.) [DA] was only increased
during the second time bin. (G–I) Changes in pH units following infusions
of cumulatively increasing doses of morphine compared to infusions of sal-
ine. (G) The low dose of morphine did not signiﬁcantly alter pH units. (H)
Following the medium dose of morphine there was a signiﬁcant acidic shift
in pH during the ﬁrst, second and third time bins following morphine infu-
sion. (I) Additionally, high dose morphine infusion also caused an acidic
shift in local pH during the ﬁrst, second and third time bins. (J–L) To exam-
ine whether MORs were dependent on the rapid neurochemical changes fol-
lowing morphine delivery, the most effective dose of morphine was chosen
(0.5 mg/kg) to examine rapid changes in [DA] and pH following blockade
of MORs via pre-treatment with the MOR-preferring antagonist naloxone
(3.0 mg/kg, i.v.; given 15 min prior to morphine infusion). (J) A representa-
tive color plot demonstrating that following naloxone pre-treatment,
morphine-evoked increases in DA transmission and the acidic shift in pH
were eliminated. (K) Quantitatively, while the medium dose of morphine
(0.5 mg/kg) signiﬁcantly increased [DA] following a saline pre-treatment,
this effect was abolished if morphine infusion was preceded by naloxone. (L)
Naloxone pretreatment also abolished morphine-evoked changes in pH. Error
bars indicate SEM; *P < 0.05. The i.v. infusion is indicated by a blue rectan-
gle which is accurate according to the time and duration of saline or drug
infusion.
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dose of morphine (i.e., the dose that evoked the most robust effects,
0.5 mg/kg) was used. Administration of the MOR-preferring antago-
nist naloxone eliminated the morphine-evoked increases in [DA] as
demonstrated in the color plot (Fig. 2J) as well as quantiﬁcation of
the data using the same 10-s binning (Fig. 2K; F11,53.572 = 1.264,
P = 0.270).
In addition to measuring real-time DA changes, these voltammet-
ric recording conditions also measure local changes in pH (see
Fig. 1E and G) (Takmakov et al., 2010; Badrinarayan et al., 2012).
Our FSCV studies show that opioids, including oxycodone (below),
morphine and remifentanil (Vander Weele et al., 2011), all evoke
an acidiﬁcation in local pH. This novel observation may reﬂect an
increase in carbon dioxide blood concentration due to opioid-
induced respiratory depression (Thompson et al., 1995; Takmakov
et al., 2010). The low dose drug infusion did not alter pH (Fig. 2G;
P > 0.05 at all time points). However, following both the medium
and high doses, morphine caused signiﬁcant acidiﬁcation during the
second and third time bin following drug infusion (Fig. 2H, medium
dose, t81.234 = 3.681, P < 0.001; and Fig. 1I, t81.416 = 2.137,
P = 0.001). Similar to its effects on DA, pre-exposure to naloxone
eliminated acidic shifts in pH (Fig. 2J and L, F11,36.642 = 0.950,
P = 0.506).
In contrast to morphine, oxycodone caused more robust acute
changes in [DA] and acidic shifts in pH, as can be seen by inspection
of the representative color plot and corresponding traces (Fig. 3A–C).
The dose of oxycodone that evoked the greatest response (1 mg/kg)
caused a dramatic increase in [DA], composed of both a gradual rise
in concentration and a robust increase in DA transients superimposed
upon this rise (Fig. 3B). These representative examples also show
robust pH acidiﬁcation (Fig. 3C). Unlike morphine, responses follow-
ing oxycodone were highly dose-dependent. Low dose administration
of oxycodone did not signiﬁcantly elevate [DA] (Fig. 3D;
F11,73.847 = 1.495, P = 0.152). However, both medium (Fig. 3E;
F11,75.752 = 14.653, P < 0.001) and high (Fig. 3F; F11,75.752
= 14.653, P < 0.001) doses of oxycodone signiﬁcantly increased
[DA] in the second time bin following drug infusion, and [DA] contin-
ued to rise throughout the recording period (Fig. 3E and F).
Similar to its effects on DA, the low dose infusion of oxycodone
did not alter pH (Fig. 3G; P > 0.05 all time points). However, both
medium and high doses of oxycodone caused robust acidic pH
shifts beginning at the second recording bin and lasting throughout
the recording period (Fig. 3H and I; P < 0.05 at the aforemen-
tioned time points). As with morphine, naloxone pre-treatment
eliminated oxycodone-induced increases in [DA] and acidic shifts
in pH, evident from the representative color plot (Fig. 3J) and
time-averaged data (Fig. 3K and L; F11,20.194 = 1.615, P = 0.169).
Morphine and oxycodone differentially alter phasic dopamine
release events
Thus far we have shown that morphine and oxycodone caused





Fig. 3. Average acute changes in dopamine concentration and local pH in
the NAc evoked by i.v. oxycodone. (A) A representative color plot shows
increased DA transmission and an acidic shift in local pH following i.v.
administration of the high dose of oxycodone (1.0 mg/kg). (B) Current was
converted into [DA] and the trace shown represents data gathered from the
peak DA oxidation potential (see top white dotted line in Fig. 6A). Select
DA transients are identiﬁed and their respective amplitudes given. (C) Simi-
larly, current from this color plot was converted into changes in pH units
and the corresponding trace (taken from the lower dotted white line in
Fig. 6A) is shown. (D–I) [DA] and pH were binned every 10 s across the
120-s sampling window for comparison to pre-infusion values. (D–F)
Changes in [DA] during infusions of cumulatively increasing doses of oxyco-
done compared to control infusions of saline. Oxycodone-evoked increases
are dose-dependent and doses that caused increases resulted in robust and
long lasting changes. (D) The low oxycodone dose (0.1 mg/kg, i.v.; yellow),
caused no change in [DA]. (E) The medium oxycodone dose (0.5 mg/kg,
i.v.; orange) caused a signiﬁcant increase in [DA] beginning in the second
time bin and lasting for the entire recording period. (F) The high oxycodone
dose (1.0 mg/kg, i.v.; red) caused the same signiﬁcant increase in [DA] as
the medium dose, from the second time bin to the end of the recording per-
iod. (G–I) Changes in pH following infusions of cumulatively increasing
doses of oxycodone compared to infusions of saline (doses: low to high,
same colors except with white stripes). (G) The low oxycodone dose
(0.1 mg/kg, i.v.) caused no change in local pH levels. (H and I) Conversely,
the medium (0.5 mg/kg, i.v.) and high (1.0 mg/kg, i.v.) oxycodone doses
caused a signiﬁcant acidic shift in pH from the ﬁrst time bin through the
remainder of the sampling period. (J–L) The effects of oxycodone following
pretreatment of either control infusions of saline or infusions of the MOR-
preferring antagonist naloxone (3.0 mg/kg, i.v.). (J) A representative color
plot demonstrating that, following naloxone pre-treatment, oxycodone-evoked
increases in DA transmission and the acidic shift in pH are eliminated. (K)
Quantitatively, while the medium dose of oxycodone (0.5 mg/kg, i.v.) signif-
icantly increased [DA] following a saline pre-treatment, when oxycodone
delivery was preceded by naloxone it no longer increased [DA]. (L) Similar
to DA, naloxone pretreatment prevented oxycodone-induced changes in
acidic pH. Error bars indicate SEM; *P < 0.05. The i.v. infusion is indicated
by a blue rectangle which is accurate according to the time and duration of
saline or drug infusion.
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sion. In addition to overall changes in [DA], FSCV allows for
examination of distinct neurotransmission components that contrib-
ute to overall changes in [DA] which are approximated by ana-
lysing DA transients (phasic surges in [DA]). Speciﬁcally, (i) the
occurrence of phasic DA release events can be approximated by
measuring transient frequency, (ii) the magnitude of DA release
per phasic event is estimated from the transient amplitude, and
(iii) the duration of increases of DA into the extracellular space
is measured as the transient half-width. Therefore, we next ana-
lysed transient frequency, amplitude and half-width during the
15 min following each infusion to elucidate the contribution of
these speciﬁc neurotransmission components for opioid-evoked
increases in [DA].
Transient frequency
Similar to previous studies, control infusions of saline did not pro-
duce changes in transient frequency for morphine (Fig. 4A;
F14,82.910 = 1.095, P = 0.374) or oxycodone (Fig. 4B; F14,76.585
= 1.806, P = 0.053). However, following morphine delivery, tran-
sient frequency was signiﬁcantly increased above saline levels for
the ﬁrst minute after drug infusion, but not thereafter, for all doses
tested (Fig. 4A; main effect of time: low dose, F14,63.338 = 4.774,
P < 0.001; medium dose, F14,68.048 = 7.297, P < 0.001; high dose,
F14,58.068 = 4.895, P < 0.001; ﬁrst minute after infusion: low dose,
t76.067 = 2.762, P = 0.007; medium dose, t(81.234) = 6.772,
P < 0.001; high dose, t71.550 = 5.099, P < 0.001). In contrast to
morphine, minute-by-minute analysis of transient frequency follow-
ing oxycodone delivery showed a dose-dependent increase in tran-
sient frequency with the low dose causing no increase (Fig. 4B;
F14,65.414 = 0.541, P = 0.899), the medium dose increasing transient
frequency for most time points (Fig. 4B; F14,62.633 = 8.453,
P < 0.001) and the high dose signiﬁcantly increasing transient fre-
quency over saline controls for the entire 15-min recording period
(Fig. 4B; F14,60.880 = 8.103, P < 0.001). Thus, given that transient
frequency is an approximation to the number of phasic DA release
events, these data strongly suggest that oxycodone, but not mor-
phine, causes an increase in the occurrence of phasic surges of high
concentration DA release events in the NAc.
Transient amplitude
Representative color plots taken ~ 2 min following morphine
(Fig. 5A) and oxycodone (Fig. 5B) infusions demonstrate the robust
differences in transient amplitudes following delivery of these differ-
ent opioids, with oxycodone evoking higher concentration transients
than morphine; this is further illustrated by the insets of representa-
tive transients within these color plots (Fig. 5A and B). Again, for
statistical analysis, mean amplitudes were binned across 1-min time
periods (Fig. 5C and D). For both morphine (Fig. 5C;
F14,65.061 = 0.848, P = 0.616) and oxycodone (Fig. 5D;
F14,65.107 = 1.394, P = 0.182) subjects, control saline infusions did
not signiﬁcantly alter mean transient amplitude compared to the
baseline period. As with transient frequency, morphine caused an
increase in transient amplitude within the ﬁrst minute immediately
following drug infusion for all doses (low dose, t61.269 = 2.237,
P = 0.029; medium dose, t89.211 = 1.314, P < 0.001; high dose,
t65.760 = 2.505, P = 0.015) but not thereafter (Fig. 5C). However,
oxycodone dose-dependently increased transient amplitude: the low
dose of oxycodone failed to increase transient amplitude (Fig. 5D;
F14,58.642 = 0.608, P = 0.847), the medium increased amplitude for
7 min (Fig. 5D; main effect, F14,70.005 = 2.268, P = 0.013) and the
high dose signiﬁcantly increased amplitude for 11 min (Fig. 5D;
main effect, F14,75.438 = 2.9905, P < 0.001).
Transient half-width
In contrast to transient frequency and amplitude, neither opioid
robustly altered transient half-width (Fig. 6). Example [DA] traces
in Fig. 6 are taken from the color plots shown in Fig. 5. Inspection
of individual traces following morphine (Fig. 6A) and oxycodone
(Fig. 6B) delivery, which include representative half-width values
(as well as the mean for the trace), show that neither opioid sub-
stantially altered DA uptake, as determined by transient half-width
values. For quantiﬁcation of the data, data were binned minute-by-
minute in the same manner as was done for transient frequency and
amplitude. This analysis shows that while saline and low dose mor-
phine infusions did not signiﬁcantly increase transient half-width,
the medium dose of morphine signiﬁcantly increased half-width at
the 1- and 4-min time points (t104.945 = 2.787; P = 0.006). There
was also a signiﬁcant increase 1 min following delivery of the high
dose (Fig. 6D; t84.328 = 2.121, P = 0.037). Conversely, oxycodone
administration did not alter transient half-width at any time point
across all doses tested (Fig. 6E; low dose, F14,60.054 = 0.483,
P = 0.933; medium dose, F14,64.918 = 0.862, P = 0.602; high dose,
F14,67.861 = 0.673, P = 0.793). Thus, in contrast to transient fre-
quency and amplitude, transient half-width showed not robust
changes following infusion of either opioid, suggesting that slowing




Fig. 4. Dopamine transient frequency following administration of morphine
or oxycodone. (A) and (B) Transient events were binned every min for the
duration of the 15 min recording intervals following each drug dose and
compared to the average post-saline frequency. (A) Transient data per min
following morphine infusions. While morphine failed to affect transient fre-
quency across the entire 15 min recording period, all doses of morphine elic-
ited a signiﬁcant increase in transient frequency during the ﬁrst minute
following drug infusion compared to saline controls. (B) Oxycodone-evoked
increases in DA transient frequency were highly dose-dependent. While the
low dose infusion of oxycodone did not increase transient frequency, the
medium dose increased DA transients for most time points and infusion of
the high dose of oxycodone elevated transient frequency for the entire dura-
tion of the recording period. Error bars indicate SEM. *Indicates statistically
signiﬁcant increases (P < 0.05).
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Core–shell differences following oxycodone but not morphine
delivery
A common feature of the primary rewarding effects of drugs of
abuse is that they evoke greater [DA] within the NAc shell than the
NAc core (Pontieri et al., 1995; Ito et al., 2000; Frank et al.,
2008). To determine whether oxycodone and morphine evoke
greater [DA] in the shell than the core, we conducted one-half of
our FSCV measurements in the NAc core and the other half in the
NAc shell (Fig. 7A). While our previous studies using FSCV to
examine cocaine-evoked DA transmission showed dramatic core–
shell differences (Aragona et al., 2008, 2009), the present study
revealed only modest core–shell differences following opioid deliv-
ery. Indeed, morphine administration, at all doses tested, produced
nearly equivalent increases in [DA] across the NAc core and shell
(Fig. 7A; main effect of subregion: low dose, F1,8.427 = 1.648,
P = 0.233; medium dose, F1,7.866 = 0.519, P = 0.492; high dose,
F1,6.839 < 0.001, P = 0.984). However, oxycodone delivery resulted
in a modest, but signiﬁcantly higher, increase in [DA] within the
NAc shell following delivery of the medium dose (from 60 to
120 s; Fig. 7B; t71.577 = 2.302, P = 0.024 for bin 6, and contin-
uing P < 0.001 for bins 7–12) and the high dose of oxycodone
(during the last two time bins, 100–120 s, t65.738 = 2.060,
P = 0.043, and t63.350 = 2.197, P = 0.032). In addition to causing a
greater increase in [DA] in the NAc shell, the medium and high
(but not the low) doses of oxycodone caused greater increases in
the frequency and amplitude of DA transients within the NAc shell
than in the core (Table 1).
A positive control to test for electrode ﬁdelity was the infusion of
the DA autoreceptor blocker raclopride at a dose (1.0 mg/kg) known
to induce burst ﬁring and forebrain DA release (Andersson et al.,
1995). Consistent with previous studies, [DA] levels were signiﬁ-
cantly higher within the NAc shell than the NAc core across multi-
ple time points (Fig. 8C and F; t116.807 = 2.043, P = 0.043;
t107.583 = 2.112, P = 0.037; t99.064 = 2.601, P = 0.011). Thus,
these data demonstrate that drugs that cause DA neuron ﬁring,
presumably equally into the NAc core and shell, result in a more
modest preferential enhancement of [DA] within the NAc shell
which is probably due to reduced uptake in the NAc shell compared





Fig. 6. Dopamine transient half-width following administration of morphine
or oxycodone. (A) A representative [DA] trace (that corresponds to the color
plot shown in Fig 4B) showing the recording ~2 min following high dose
morphine infusion within the NAc shell, and (B) a similar [DA] trace follow-
ing a high dose oxycodone infusion. (C) and (D) Mean transient half-width
was binned every min for the duration of the 15 min recording interval
and compared to the average half-width post-control saline infusion.
(C) Morphine-evoked increases in DA transient half-width measured across
1 min time bins shows that only subjects that received low dose morphine
infusion failed to increase transient half-width. Following medium and high
dose infusions of morphine, transient half-width was signiﬁcantly increased
at the 3 min mark following the medium dose of morphine and during the
ﬁrst min following the high dose. There was a trend towards signiﬁcance
during the ﬁrst min following the medium dose of morphine. (D) At all
tested doses, oxycodone failed to increase transient half-width. Error bars
indicate SEM. *indicates statistically signiﬁcant increases (P < 0.05). #Indi-





Fig. 5. Dopamine transient amplitude following administration of morphine
or oxycodone. (A) A representative color plot showing a recording ~2 min
following a high dose morphine infusion within the NAc shell, and (B) a
similar recording following a high dose oxycodone infusion. Insets show a
zoomed in inspection of individual transients and provides their amplitudes.
(C) and (D) Transient events were binned every min for the duration of the
15 min recording interval and compared to the average amplitude post-con-
trol saline infusion. (C) As with transient frequency, morphine-evoked
increases in DA transient amplitude measured across 1 min time bins shows
that regardless of whether subjects received low, medium or high doses of
morphine, transient amplitude was signiﬁcantly increased above levels of
those gathered from saline controls for only the ﬁrst min following morphine
infusion. (D) Oxycodone-evoked increases in DA transient amplitude were
dose-dependent. The low dose had no effect on transient amplitude; however,
both medium and high doses of oxycodone elevated transient amplitude
for the majority of the recording period. Error bars indicate SEM. *Indicates
statistically signiﬁcant increases (P < 0.05).
© 2014 Federation of European Neuroscience Societies and John Wiley & Sons Ltd
European Journal of Neuroscience, 40, 3041–3054
3048 C. M. Vander Weele et al.
Rapid microdialysis with mass spectrometry revealed
coincident peaks in dopamine and GABA concentration
following morphine, but not oxycodone, delivery, consistent
with the FSCV results
The sub-second measurements provided by FSCV described above
revealed that morphine and oxycodone evoked very different phasic
patterns in DA transmission in the NAc. However, FSCV is opti-
mised for measuring phasic changes in DA and pH. Therefore we
employed rapid microdialysis coupled with HPCL-MS (1-min sam-
pling resolution) to measure 16 compounds following morphine and
oxycodone delivery (Fig. 9A and B). Another limitation of FSCV is
that the background subtraction results in the inability to measure
changes in [DA] over long periods of time (i.e., over many min-
utes). Again, microdialysis with HPLC-MS allows minute-by-minute
changes after drug delivery for many chemical species (Fig. 9A and B)
(Song et al., 2012).
With respect to DA transmission within the NAc (Fig. 9C) fol-
lowing opioid delivery, the microdialysis HPLC-MS data are consis-
tent with the FSCV data shown above. While saline infusions (i.v.)
did not signiﬁcantly alter [DA] (Fig. 9D), i.v. infusion of oxycodone
produced a signiﬁcant increase in [DA], compared to baseline and
saline infusion levels, that lasted the duration of the recording period
(Fig. 9D; main effect, F40,69.766 = 1.693, P = 0.027). In contrast,




Fig. 7. Morphine and oxycodone, in general, do not evoke greater dopamine
release in the NAc shell compare to the core. (A) Histology for both mor-
phine subjects (n = 8) recorded from the NAc core (n = 4) or shell (n = 4)
and oxycodone subjects (n = 8) - NAc core (n = 4) or shell
(n = 4) - were recorded from similar locations within the NAc. (B) [DA] for
morphine subjects were binned every 10 s across the 120 s sampling window
encompassing i.v. infusions (from left to right: saline; 0.1 mg/kg; 0.5 mg/kg;
1.0 mg/kg). Morphine did not signiﬁcantly elevate [DA] in the NAc shell
[open circles] compared to the core [closed circles]. (C) [DA] for oxycodone
subjects were binned every 10 s across the 120 s sampling window encom-
passing i.v. infusions (from left to right: saline; 0.1 mg/kg; 0.5 mg/kg;
1.0 mg/kg). Oxycodone did not signiﬁcantly elevate [DA] in the NAc shell
[open circles] compared to the core [closed circles] at the low 0.1 mg/kg
dose. Conversely, oxycodone caused a modest, but signiﬁcant increase in
[DA] within the NAc shell compared to the core at the medium (0.5 mg/kg)
and high (1.0 mg/kg) doses. Error bars indicate SEM. The i.v. infusion is
indicated by a blue rectangle which is accurate according to the time and
duration of saline or drug infusion.
A B
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Fig. 8. Raclopride evokes greater dopamine concentration within the NAc
shell compared to the NAc core. (A) A representative color plot of
increased DA transmission within the NAc shell following i.v. raclopride
infusion (1.0 mg/kg; which followed the opioid infusions described above).
(B) A representative color plot is shown from the NAc core following the
same dose of raclopride. (C) Corresponding [DA] traces associated with the
color plots. [DA] is robustly elevated raclopride infusion in both the core
and shell. The resulting [DA] traces associated with these color plots show
that autoreceptor blockade causes an increase in DA transients superimposed
on a gradual rise in [DA]. (D) Quantitative data of raclopride-evoked
increases in [DA] within the NAc core and shell. Despite the similarities in
the nature of raclopride-evoked increases in phasic DA release, increased
[DA] in the shell is signiﬁcantly higher compared to that evoked within the
NAc core from 30 to 120 s following raclopride infusion. Error bars indicate
SEM. *Indicates statistically signiﬁcant increases (P < 0.05).
Table 1. Frequency and amplitude of DA transients in the NAc shell vs. the core following i.v. oxycodone
Transient frequency Transient amplitude
Shell Core F1,18 P Shell Core F1,16 P
Low 5.6  1.1 3.3  1.1 2.690 0.118 34.2  4.5 31.2  2.1 0.272 0.609
Medium 9.5  0.3 5.0  1.1 11.234 0.004 54.3  3.4 35.9  2.0 12.010 0.003
High 10.2  0.5 5.8  4.0 10.580 0.004 65.3  5.4 38.0  4.0 22.649 < 0.001
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Fig. 9. Rapid sampling microdialysis coupled with HPLC-MS reveals differential changes in dopamine transmission within the NAc between morphine and oxyco-
done. (A) Dialysate was collected every minute (step 1) and immediately derivatised with benzoyl chloride (step 2). Internal standards were added to improve quanti-
ﬁcation (step 3), and fractions were analysed with HPLC-MS (step 4). A representative total ion chromatogram of a dialysate sample reveals that a tremendous
numbers of analytes can be measured using this technology compared to traditional microdialysis. (B) Heatmap representing mean percentage changes under base-
line conditions and changes following i.v. morphine (0.5 mg/kg; n = 4) and oxycodone (0.5 mg/kg, i.v.; n = 5) delivery. (C). Histological representation of all
probe placements for subjects receiving morphine (purple) and oxycodone (orange). (D) Normalised changes in [DA] within the NAc (core and shell combined).
Baseline levels are shown in gray and control i.v. infusions of saline (white circles) did not signiﬁcantly increase [DA] above basal levels. Infusion of morphine
(0.5 mg/kg i.v.; purple circles) signiﬁcantly increased [DA] for 1 min; levels then returned to baseline. Consistent with FSCV data, oxycodone (orange circles)
caused a signiﬁcant increase in [DA] immediately and remained elevated for the entire sampling period. (E) As a positive control, a drug cocktail known to robustly
increase [DA] (the D2 antagonist raclopride and the DAT blocker cocaine) evoked an extremely robust increase in [DA] (~ 5000%). (F) Consistent with changes in
[DA], the DA metabolite 3-MT trended toward signiﬁcance in the ﬁrst two recording blocks following oxycodone administration, and was signiﬁcantly increased
during the remainder of the recording session. However, following morphine, 3-MT was largely unchanged following morphine delivery with the exception of a
trend toward signiﬁcance in the sixth recording session. (G) Following oxycodone, the DA metabolite HVA showed a trend toward signiﬁcance in the seventh ses-
sion and was signiﬁcantly increased in the ﬁnal two recording bins. However, HVA levels remained unchanged following morphine delivery. (H) The DA metabo-
lite DOPAC was signiﬁcantly elevated in the ﬁnal two recording bins following oxycodone delivery, but showed no change following morphine infusion. (I) The
only neurotransmitter that showed a similar pattern of transmission that was similar to DA was GABA transmission following morphine delivery. GABA was signif-
icantly elevated following morphine, but not oxycodone, infusion and this increase was only signiﬁcant during the ﬁrst time point following drug infusion. (J) There
was a trend toward a signiﬁcant increase in glutamate concentration in the ﬁnal recording session following morphine but not oxycodone delivery. (K) Morphine
infusion signiﬁcantly decreased taurine concentration, beginning at the third time bin, and remained decreased for the duration of the recording period. Conversely,
oxycodone infusion had no effect on taurine levels. Error bars indicate SEM; *P < 0.05; #P < 0.09.
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during the ﬁrst minute immediately following drug administration
(t107.996 = 5.303, P < 0.001). Finally, we used a positive control to
demonstrate the validity of these rapid dialysis measures. A combi-
nation of the D2 DA receptor antagonist raclopride and the DA
transporter blocker, cocaine, which has been shown to cause a
synergistic increase in [DA] (Rouge-Pont et al., 2002; Aragona
et al., 2008), was administered. Consistent with these previous dial-
ysis studies, cocaine in the presence of raclopride caused an extre-
mely large increase in DA release (Fig. 9E; P < 0.05, minutes
70–76).
Changes in concentrations of DA metabolites are consistent with
the morphine–oxycodone differences observed for [DA] (Fig. 9F–H).
Speciﬁcally, oxycodone, but not morphine, caused increases in the
DA metabolites 3-MT (Fig. 9F; oxycodone, F9,14.670 = 2.596,
P = 0.051; morphine, F9,5.623 = 0.879, P = 0.589), HVA (Fig. 9G;
last two oxycodone bins respectively, t23.020 = 2.645, P = 0.014 and
t(22.939) = 3.079, P = 0.005; morphine, F9,11.182 = 1.030,
P = 0.473), and DOPAC (Fig. 9H; last two oxycodone bins respec-
tively, t29.887 = 2.080, P = 0.046 and t29.887 = 2.510, P = 0.018;
morphine, F9,12.910 = 0.325, P = 0.951). Microdialysis with HPLC-
MS provides the opportunity to investigate simultaneous changes in
multiple neurotransmitter concentrations following morphine and
oxycodone. As described above, morphine, but not oxycodone,
caused a brief increase in [DA] that rapidly returned to baseline and
this result was observed using both FSCV and microdialysis (see
above). It is therefore interesting that morphine, but not oxycodone,
delivery produced a coincident increase in GABA concentration dur-
ing the same time point of the initial peak in [DA] following drug
delivery but not thereafter (Fig. 9I; t29.99 = 3.218, P = 0.003).
Given GABA’s inhibitory role in neurotransmission, this increase in
GABA concentration following morphine may be responsible for
DA returning to baseline immediately after its initial peak following
delivery. This brief morphine-evoked increase in GABA within the
NAc is probably involved in explaining how these two opioids dif-
ferentially mediate reward.
In contrast to GABA, there was no signiﬁcant change in gluta-
mate concentration following delivery of either drug except for a
trend for an increase toward the end of the sampling period follow-
ing morphine delivery (Fig. 9J). Additionally, there was a signiﬁcant
and sustained decrease in taurine concentration following morphine
(F9,9.855 = 3.412, P = 0.035) but not oxycodone (F9,18.410 = 0.521,
P = 0.840) delivery (Fig. 9K). This decrease in taurine is interesting
because it is consistent with previous studies showing that alcohol
administration also alters NAc taurine levels (Dahchour et al.,
1994).
Regarding the remainder of the analytes detected, there were no
statistically signiﬁcant differences in neurotransmission between
morphine and oxycodone delivery (data not shown), and neither drug
caused statistically signiﬁcant differences in detected dialysate levels
of acetylcholine (oxycodone, F9,27.757 = 1.977, P = 0.081; morphine,
F9,10.732 = 0.953, P = 0.522), serotonin (oxycodone, F9,6.311 =
0.381, P = 0.908; morphine, F9,4.945 = 1.170, P = 0.455), the seroto-
nin metabolite 5-hydroxyindole-3-acetic acid (oxycodone, F9,6.173 =
0.553, P = 0.797; morphine, F9,11.631 = 1.043, P = 0.463), norepi-
nephrine (oxycodone, F9,17.258 = 0.658, P = 0.735; morphine,
F9,11.545 = 0.429, P = 0.894), the norepinephrine metabolite normeta-
nephrine (oxycodone, F9,17.326 = 0.964, P = 0.500; morphine,
F9,6.143 = 0.805, P = 0.630), serine (oxycodone, F9,17.352 = 1.012,
P = 0.467; morphine, F9,13.201 = 0.711, P = 0.691), adenosine (oxy-
codone, F9,16.407 = 0.297, P = 0.965; morphine, F9,11.320 = 1.253,
P = 0.354), histamine (oxycodone, F9,5.829 = 1.509, P = 0.321;
morphine, F9,4.971 = 0.838, P = 0.616) or aspartate (oxycodone,
F9,18.268 = 1.217, P = 0.343; morphine, F9,12.052 = 0.943, P =
0.525). Data are represented in heat maps in Fig. 9B.
Discussion
Prescription opioid abuse is a rapidly growing epidemic (Compton
& Volkow, 2006; McCabe et al., 2013b). In particular, oxycodone
is among the most commonly abused opioids (McCabe et al.,
2013a,b). While there is no doubt that greater availability of this
prescription drug has contributed to this rise in abuse, there is grow-
ing evidence suggesting that oxycodone may be more potent with
respect to its ability to promote addictive behaviors (Stoops et al.,
2010; Comer et al., 2013). For example, in the clinical realm, oxy-
codone administration to human heroin addicts, compared to other
opioids, caused robust reinforcing effects with no increases in nega-
tive effects (Comer et al., 2008). Further, in the same study, a ver-
bal report from a heroin-dependent individual stated that oxycodone
is the ‘Rolls Royce’ of opioids and that it produces a ‘smooth high’
(Comer et al., 2008). While recent studies have begun to investigate
the inﬂuence of oxycodone on behavior and brain processes (Zhang
et al., 2009, 2014; Niikura et al., 2013; Mayer-Blackwell et al.,
2014), it has remained unclear whether this drug differentially alters
neurotransmission associated with reward and motivation compared
to other opioids. Here, we demonstrate that DA transmission within
the NAc, a key neurobiological component of motivation, is starkly
different following oxycodone compared to morphine delivery.
Moreover, we reveal that morphine delivery is associated with a
coincident surge in DA and GABA concentration immediately fol-
lowing drug delivery in the NAc. This increase in GABA concentra-
tion observed following morphine, but not oxycodone, may explain
why [DA] quickly returns to baseline levels following delivery of
morphine but not of oxycodone.
Using two rapid neurochemical measurement technologies, we
reveal robust oxycodone-evoked increases in [DA]. The present
FSCV experiment detected that [DA]s achieve levels as high as
500 nM in the NAc shell, and the microdialysis study shows that
oxycodone-evoked increase in [DA] is stable and long-lasting.
Indeed, drug-evoked increases in [DA] as well as DA transients
remain elevated throughout the 15-min recording period. Con-
versely, both the microdialysis and FSCV experiments reveal that
morphine evokes an initial rapid increase in [DA] only during the
ﬁrst minute following drug infusion. Importantly, this morphine-
evoked increase in [DA] was coincident with an increase in GABA
concentration, which was also elevated only within the ﬁrst 1-min
time bin following drug infusion.
Greater increases in [DA] following oxycodone than following
morphine delivery was also associated with a greater frequency and
amplitude of phasic DA release events (DA transients) but was not
associated with slowed reuptake as measured by transient half-width.
DA transients originate from burst ﬁring of DA-containing neurons
within the midbrain (Aragona et al., 2008; Sombers et al., 2009;
Owesson-White et al., 2012). This ﬁnding that oxycodone caused a
dramatic increase in DA transients is of interest because strong argu-
ments continue to be made that the ability of a drug to potentiate
DA transients is closely associated with a drug’s potential risk for
addiction (Covey et al., 2014).
Despite both being MOR agonists, morphine and oxycodone have
distinct pharmacokinetic and pharmacodynamic properties that may
contribute to their different effects on DA transmission (Nielsen
et al., 2007; Lemberg et al., 2009). Although oxycodone has a
lower afﬁnity for the MOR than morphine (Chen et al., 1991; Lalo-
vic et al., 2006), oxycodone crosses the blood–brain barrier more
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readily than morphine (Villesen et al., 2006), and unbound concen-
trations of oxycodone are higher in the brain than in the blood fol-
lowing i.v. administration, suggesting that oxycodone is actively
transported across the blood–brain barrier (Bostr€om et al., 2006,
2008; Villesen et al., 2006). Indeed, for the same unbound concen-
trations of oxycodone and morphine in the blood, unbound oxyco-
done in the brain is as much as six times higher than morphine
(Bostr€om et al., 2008). Additionally, ligand-directed signaling could
contribute to differences in drug-evoked DA transmission, as mor-
phine and oxycodone have different intrinsic efﬁcacies and receptor
internalisation proﬁles (Lester & Traynor, 2006; Peckham & Tray-
nor, 2006; Melief et al., 2010). Finally, morphine and oxycodone
have different metabolic pathways, and the actions of their respec-
tive metabolites differ, which may potentially contribute to differen-
tial drug-evoked [DA]s (Kalso, 2007). Future studies are needed to
investigate the roles of these different pharmacokinetic and pharma-
codynamic properties of morphine and oxycodone on altering DA
transmission.
Mechanistically, as the coincident increase in GABA concentra-
tion was associated with morphine, but not oxycodone, delivery,
it is an intriguing possibility that the surge in GABA could be
directly related to the rapid return of DA to its baseline. In other
words, GABA may mediate the inhibitory mechanism which rap-
idly shuts down the initial morphine-evoked increases DA trans-
mission. Thus, the present neurochemical data provide a potential
mechanism regarding differences in opioid-evoked changes in
[DA] between morphine and oxycodone. There are at least two
possible mechanisms whereby GABA inhibits DA transmission in
the NAc. First, as local perfusion of morphine into the NAc
increases GABAergic signaling (Sun et al., 2011), it is possible
that increased GABA levels in the NAc may activate GABAA
receptors on DA terminals and thereby reduce DA release (Aono
et al., 2008; Saigusa et al., 2008). In contrast, oxycodone may
promote greater MOR activation of GABAergic interneurons,
reducing local GABA levels and subsequently disinhibiting DA
release from terminals (Aono et al., 2008).
Second, the fact that morphine, but not oxycodone, increases
GABA transmission within the NAc may be due to increased mor-
phine-induced ﬁring of GABAergic neurons in the VTA projecting
to the NAc (van Zessen et al., 2012). This is an intriguing possibil-
ity because previous studies have shown that a single injection of
morphine can produce a conditioned place aversion in drug-na€ıve
rats (Parker et al., 2002; but see Fenu et al., 2006). There are
numerous anecdotal reports describing how opioids are initially
aversive before they become rewarding, and this initial aversion
may involve a GABAergic mechanism. Recent studies have care-
fully identiﬁed that place aversions are indeed mediated by activa-
tion of these GABAergic projection neurons from the VTA to the
NAc (Tan et al., 2012). Regardless of the speciﬁc mechanism, the
present neurochemical data provide novel explanatory power regard-
ing why morphine has long been known to be initially aversive and
may further explain why oxycodone is a preferred opioid (Comer
et al., 2008).
Previous work has suggested that activation of MORs on GAB-
Aergic interneurons within the VTA deactivate these interneurons,
resulting in the disinhibition of DA neuron ﬁring and an increase
in DA neuron burst ﬁring, and elevated [DA] release from fore-
brain terminals (Gysling & Wang, 1983; Johnson and North,
1992, Matsui and Williams, 2011). However, there are additional
mechanisms that remain to be elucidated as oxycodone, but not
morphine, causes a substantial increase in DA transients, and
previous studies have shown that morphine delivery causes an
overall increase DA neuron ﬁring without increasing burst ﬁring
(Gysling & Wang, 1983). Furthermore, local application of mor-
phine into the VTA increases DA neuron ﬁring rate but this is
subsequently followed by a decrease in ﬁring rate (Matthews &
German, 1984). These electrophysiology ﬁndings are consistent
with the present data, except that the aforementioned electrophysi-
ology study did not report an initial morphine-induced burst of
DA neuron activity that would coincide with the rapid morphine-
evoked DA release observed in the ﬁrst minute post-infusion. A
likely explanation for this disconnect is that most of the electro-
physiology experiments conducted decades ago only recorded
from ‘traditional’ DA neurons. Now, however, functionally and
anatomically distinct sub-populations of DA neurons with different
ﬁring properties have been discovered (Ikemoto, 2007; Lammel
et al., 2008, 2011). Interestingly, a subset of DA neurons along
the midline of the VTA are far more susceptible to bursting
(Lammel et al., 2008) and therefore are a strong candidate to be
the DA neurons responsible for this initial morphine-evoked DA
release. Future studies are needed to test this hypothesis.
As discussed above, it is possible that morphine-evoked increases
in GABA concentration mediate early aversive processing upon ini-
tial morphine exposure. However, morphine can also be highly
rewarding. Indeed, activation of MORs can promote consumption of
palatable foods and has been linked to pleasure (Will et al., 2003;
Kelley, 2004; Berridge & Kringelbach, 2013). Therefore, future
studies are needed to determine how increases in GABA concentra-
tions in the NAc differentially contribute to morphine reward com-
pared to oxycodone reward.
Conclusion
This is the ﬁrst study to compare the initial rapid neurochemical
changes in the NAc core and shell following delivery of two highly
abused opioids, morphine and oxycodone. FSCV and rapid microdi-
alysis HPLC-MS revealed that oxycodone caused a greater increase
in [DA] in the NAc than did morphine. Oxycodone robustly
increased [DA] in both sub-regions of the NAc, albeit greater within
the NAc shell. These increases lasted the entire recording period
and, in addition to increasing [DA], oxycodone robustly increased
the frequency and amplitude of DA transients. However, with the
exception of increasing DA metabolites, rapid microdialysis showed
that oxycodone caused no appreciable change to other signaling
molecules. Conversely, morphine caused a coincident surge in DA
and GABA concentration within the ﬁrst minute following drug
delivery but not thereafter. However, despite these differences both
opioids are highly addictive when abused. As stated above, there is
growing evidence that oxycodone appears to be a preferred opioid
of abuse and its abuse continues to increase tremendously. Thus, it
is essential to understand how drugs differentially alter neurochemis-
try if we hope to provide relief to addicts, and this begins by using
in vivo tools, such as those described herein, to reveal how different
drugs differentially impact brain signaling systems that powerfully
takeover behavior.
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